Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology, ASH, Annual Meeting and Exposition in San Diego, California from December 7-10, 2024. Key presentations and publications at ASH 2024 will include: An oral presentation on results from the Phase 3 ENERGIZE-T study evaluating mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia versus placebo. Alongside the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent alpha- or beta-thalassemia previously presented at the 2024 European Hematology Association (EHA) Congress, these data support mitapivat’s potential as an oral, disease-modifying therapy across the full range of patients with thalassemia regardless of transfusion status. A poster presentation of a Phase 1 study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of tebapivat in patients with sickle cell disease, providing further evidence that PK activation may have beneficial effects in this patient population. A trial-in-progress publication that outlines the Phase 2b study evaluating the efficacy and safety of tebapivat in patients with anemia due to lower-risk myelodysplastic syndromes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGIO:
- Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank
- Agios Pharmaceuticals Reports Robust Q3 2024 Results
- Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11
- Agios Pharmaceuticals (AGIO) Q3 Earnings Cheat Sheet
- Agios Pharmaceuticals completes enrollment of Phase 3 RISE UP study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
